These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38831860)

  • 1. Nusinersen therapy changed the natural course of spinal muscular atrophy type 1: What about spine and hip?
    Yasar NE; Ozdemir G; Uzun Ata E; Ayvali MO; Ata N; Ulgu M; Dumlupınar E; Birinci S; Bingol I; Bekmez S
    J Child Orthop; 2024 Jun; 18(3):322-330. PubMed ID: 38831860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug treatment for spinal muscular atrophy type I.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy.
    Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Schwersenz I; Walter MC; Baumann M; Baumgartner M; Deschauer M; Eisenkölbl A; Flotats-Bastardas M; Hahn A; Horber V; Husain RA; Illsinger S; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Stögmann E; Trollmann R; Vill K; Weiß C; Wiegand G; Ziegler A; Lochmüller H; Kirschner J;
    Brain; 2023 Feb; 146(2):668-677. PubMed ID: 35857854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
    Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
    Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study.
    Yang H; Tao Q; Li D; Yang J; Cai Q; Gan J; Huang S; Luo R
    BMC Neurol; 2023 Jan; 23(1):35. PubMed ID: 36690929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular Atrophy.
    Kokaliaris C; Evans R; Hawkins N; Mahajan A; Scott DA; Sutherland CS; Nam J; Sajeev G
    Adv Ther; 2024 Jun; 41(6):2414-2434. PubMed ID: 38705943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive institutional overview of intrathecal nusinersen injections for spinal muscular atrophy.
    Mousa MA; Aria DJ; Schaefer CM; Kaye RD; Abruzzo TA; Bernes SM; Willard SD; Riemann MC; Towbin RB
    Pediatr Radiol; 2018 Nov; 48(12):1797-1805. PubMed ID: 30022258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nusinersen Initiation After Onset of Weakness Does Not Prevent Progression of Hip Instability.
    Kuong EE; Ip HNH; So NLW; To MKT; Chow W; Wong JSH; Chan SHS
    J Pediatr Orthop; 2024 Aug; 44(7):e657-e661. PubMed ID: 38689487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy.
    Hepkaya E; Kılınç Sakallı AA; Ülkersoy İ; Başkan AK; Arslan H; Meral Ö; Dilek TD; Güler S; Saltık S; Çokuğraş H
    Pediatr Int; 2022 Jan; 64(1):e15310. PubMed ID: 36310036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nusinersen Administration Via an Intrathecal Port in a 16-Year-Old Spinal Muscular Atrophy Patient with Profound Scoliosis.
    Flotats-Bastardas M; Linsler S; Zemlin M; Meyer S
    Pediatr Neurosurg; 2020; 55(1):54-57. PubMed ID: 31722365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nusinersen Treatment for Spinal Muscular Atrophy: Retrospective Multicenter Study of Pediatric and Adult Patients in Kuwait.
    AlTawari A; Zakaria M; Kamel W; Shaalan N; Elghazawi GAI; Ali MEA; Salota D; Attia A; Elanay EEA; Shalaby O; Alqallaf F; Mitic V; Bastaki L
    Neurol Int; 2024 Jun; 16(3):631-642. PubMed ID: 38921951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nusinersen for Spinal Muscular Atrophy Type I with Chronic Respiratory Failure: A Retrospective Study in South Korea.
    Shin HJ; Na JH; Lee H; Lee YM
    Yonsei Med J; 2023 Dec; 64(12):705-711. PubMed ID: 37992742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrathecal Administration of Nusinersen Using the Ommaya Reservoir in an Adult with 5q-Related Spinal Muscular Atrophy Type 1 and Severe Spinal Deformity.
    Papaliagkas V; Foroglou N; Toulios P; Moschou M; Gavriilaki M; Notas K; Chatzikyriakou E; Zafeiridou G; Arnaoutoglou M; Kimiskidis VK
    Case Rep Neurol; 2021; 13(3):710-715. PubMed ID: 34950009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
    Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM
    Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nusinersen treatment of older children and adults with spinal muscular atrophy.
    Konersman CG; Ewing E; Yaszay B; Naheedy J; Murphy S; Skalsky A
    Neuromuscul Disord; 2021 Mar; 31(3):183-193. PubMed ID: 33608138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scoliosis in Spinal Muscular Atrophy Type 1 in the Nusinersen Era.
    Al Amrani F; Amin R; Chiang J; Xiao L; Boyd J; Law E; Nigro E; Weinstock L; Stosic A; Gonorazky HD
    Neurol Clin Pract; 2022 Aug; 12(4):279-287. PubMed ID: 36382115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous progression patterns of scoliosis, pelvic obliquity, and hip subluxation/dislocation in non-ambulatory neuromuscular patients: an approach to deformity documentation.
    Patel J; Shapiro F
    J Child Orthop; 2015 Oct; 9(5):345-56. PubMed ID: 26423268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience.
    Łusakowska A; Wójcik A; Frączek A; Aragon-Gawińska K; Potulska-Chromik A; Baranowski P; Nowak R; Rosiak G; Milczarek K; Konecki D; Gierlak-Wójcicka Z; Burlewicz M; Kostera-Pruszczyk A
    Orphanet J Rare Dis; 2023 Aug; 18(1):230. PubMed ID: 37542300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and Electrophysiological Changes in Pediatric Spinal Muscular Atrophy after 2 Years of Nusinersen Treatment.
    Axente M; Mirea A; Sporea C; Pădure L; Drăgoi CM; Nicolae AC; Ion DA
    Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.
    Weiß C; Ziegler A; Becker LL; Johannsen J; Brennenstuhl H; Schreiber G; Flotats-Bastardas M; Stoltenburg C; Hartmann H; Illsinger S; Denecke J; Pechmann A; Müller-Felber W; Vill K; Blaschek A; Smitka M; van der Stam L; Weiss K; Winter B; Goldhahn K; Plecko B; Horber V; Bernert G; Husain RA; Rauscher C; Trollmann R; Garbade SF; Hahn A; von der Hagen M; Kaindl AM
    Lancet Child Adolesc Health; 2022 Jan; 6(1):17-27. PubMed ID: 34756190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.